Ciprofloxacin treatment failure in a case of typhoid fever caused by Salmonella enterica serotype Paratyphi A with reduced susceptibility to ciprofloxacin

被引:42
作者
Dimitrov, Tzonyo
Udo, Edet E.
Albaksami, Osama
Kilani, Abdul A.
Shehab, El-Din M. R.
机构
[1] Infect Dis Hosp, Microbiol Sect, Dept Med Labs, Safat 13048, Kuwait
[2] Kuwait Univ, Fac Med, Dept Microbiol, Safat 13110, Kuwait
[3] Infect Dis Hosp, Dept Pediat, Safat 13048, Kuwait
[4] Infect Dis Hosp, Dept Med, Safat 13048, Kuwait
关键词
D O I
10.1099/jmm.0.46773-0
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
This report describes a case of ciprofloxacin treatment failure in a patient with enteric fever caused by Salmonella enterica serotype Paratyphi A. The organism was isolated from a blood culture from a patient who was treated with oral ciprofloxacin (500 mg every 12 h) for 13 days. The organism showed reduced susceptibility to ciprofloxacin (MIC 0.75 pg ml(-1)) and was resistant to nalidixic acid. The patient was then placed on intravenous ceftriaxone (1 g every 12 h) and responded within 3 days. The patient was discharged after 9 days on ceftriaxone with no relapse on follow-up. This case adds to the increasing incidence of treatment failures with ciprofloxacin in typhoid fever caused by typhoid salmonellae with reduced susceptibility to ciprofloxacin. It also highlights the inadequacy of current laboratory methods for fluoroquinolone susceptibility testing in adequately predicting in vivo activity of ciprofloxacin against typhoid salmonellae and supports calls for new guidelines for fluoroquinolone susceptibility testing of these organisms.
引用
收藏
页码:277 / 279
页数:3
相关论文
共 14 条
  • [1] Asna SMZH, 2003, JPN J INFECT DIS, V56, P32
  • [2] Drug-resistant Salmonella enterica serotype Paratyphi A in India
    Chandel, DS
    Chaudhry, R
    Dhawan, B
    Pandey, A
    Dey, AB
    [J]. EMERGING INFECTIOUS DISEASES, 2000, 6 (04) : 420 - 421
  • [3] Incidence of bloodstream infections in a speciality hospital in Kuwait: 8-year experience
    Dimitrov, TS
    Panigrahi, D
    Emara, M
    Al-Nakkas, A
    Awni, F
    Passadilla, R
    [J]. MEDICAL PRINCIPLES AND PRACTICE, 2005, 14 (06) : 417 - 421
  • [4] Comparative studies of mutations in animal isolates and experimental in vitro- and in vivo-selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field
    Giraud, E
    Brisabois, A
    Martel, JL
    Chaslus-Dancla, E
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) : 2131 - 2137
  • [5] Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from southeast Asia
    Hakanen, A
    Kotilainen, P
    Huovinen, P
    Helenius, H
    Siitonen, A
    [J]. EMERGING INFECTIOUS DISEASES, 2001, 7 (06) : 996 - 1003
  • [6] Detection of decreased fluoroquinolone susceptibility in salmonellas and validation of nalidixic acid screening test
    Hakanen, A
    Kotilainen, P
    Jalava, J
    Siitonen, A
    Huovinen, P
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (11) : 3572 - 3577
  • [7] *NAT COMM CLIN LAB, 2005, METH DISK SUSC TESTS
  • [8] Treatment failure in a typhoid patient infected with nalidixic acid resistant S. enterica serovar Typhi with reduced susceptibility to Ciprofloxacin: a case report from Cameroon
    Nkemngu, NJ
    Asonganyi, EDN
    Njunda, AL
    [J]. BMC INFECTIOUS DISEASES, 2005, 5 (1)
  • [9] Typhoid fever
    Parry, CM
    Hien, TT
    Dougan, G
    White, NJ
    Farrar, JJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (22) : 1770 - 1782
  • [10] Piddock LJV, 2002, FEMS MICROBIOL REV, V26, P3, DOI [10.1016/S0168-6445(01)00076-6, 10.1111/j.1574-6976.2002.tb00596.x]